Cargando…
An oral cancer vaccine using a Bifidobacterium vector suppresses tumor growth in a syngeneic mouse bladder cancer model
Cancer immunotherapy using immune-checkpoint inhibitors (ICIs) such as PD-1/PD-L1 inhibitors has been well established for various types of cancer. Monotherapy with ICIs, however, can achieve a durable response in only a subset of patients. There is a great unmet need for the ICI-resistant-tumors. S...
Autores principales: | Kitagawa, Koichi, Tatsumi, Maho, Kato, Mako, Komai, Shota, Doi, Hazuki, Hashii, Yoshiko, Katayama, Takane, Fujisawa, Masato, Shirakawa, Toshiro |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society of Gene & Cell Therapy
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8449024/ https://www.ncbi.nlm.nih.gov/pubmed/34589578 http://dx.doi.org/10.1016/j.omto.2021.08.009 |
Ejemplares similares
-
An oral cancer vaccine using Bifidobacterium vector augments combination of anti-PD-1 and anti-CTLA-4 antibodies in mouse renal cell carcinoma model
por: Ueki, Hideto, et al.
Publicado: (2023) -
Antitumor effect of oral cancer vaccine with Bifidobacterium delivering WT1 protein to gut immune system is superior to WT1 peptide vaccine
por: Shirakawa, Toshiro, et al.
Publicado: (2017) -
Combination of rAd-p53 in situ gene therapy and anti-PD-1 antibody immunotherapy induced anti-tumor activity in mouse syngeneic urogenital cancer models
por: Kunimura, Naoto, et al.
Publicado: (2020) -
An oral WT1 protein vaccine composed of WT1-anchored, genetically engineered Bifidobacterium longum allows for intestinal immunity in mice with acute myeloid leukemia
por: Nakagawa, Natsuki, et al.
Publicado: (2022) -
Enhanced antitumor activity of a novel, oral, helper epitope-containing WT1 protein vaccine in a model of murine leukemia
por: Minagawa, Hikaru, et al.
Publicado: (2023)